Bioavailability of Vitamin B12 in Bread Using Fermented Faba Bean as B12 Source in Healthy Volunteers (BeanBread)
Launched by UNIVERSITY OF HELSINKI · Oct 17, 2023
Trial Information
Current as of November 06, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial, called BeanBread, is studying how well our bodies can absorb vitamin B12 from a special type of bread made with fermented faba bean flour. Typically, vitamin B12 is found in animal products, but this study explores whether it can be effectively added to plant-based foods using a specific bacterium, Propionibacterium freudenreichii. Participants will eat two different types of bread: one that contains the vitamin B12 produced by this bacterium and a control bread made with a different bacterium that does not produce B12. The goal is to see how much vitamin B12 is absorbed by the body from these breads over a couple of days.
To participate in this study, you need to be healthy, with a body mass index (BMI) between 18.5 and 35. However, certain conditions would exclude you, such as having food allergies to the study ingredients, being pregnant or breastfeeding, or using vitamin B12 supplements regularly. If you join, you will eat the study breads for two days, and your blood will be tested to measure vitamin B12 levels. This study is double-blinded, meaning neither you nor the researchers will know which bread contains the vitamin B12, ensuring fair results.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Healthy
- • Body mass index between 18.5 and 35 kg/m2
- • No exclusion criteria listed below
- Exclusion Criteria:
- • Food allergies against ingredients in foods supplemented in the study
- • pregnancy and/or breastfeeding
- • Regular use of food supplements containg B12
- • Blood donation within 3 months
- • Alcohol consumption more than 24 measures per week
- • Smoking, using snuff
- • Iron, B12 or folate deficiency
- • Anemia
- • small intestinal bacterial overgrowth (SIBO)
- • Gastritis
- • Helicobacter pylori infection
- • Acid reflux
- • Chron's disease
- • Celiac disease
- • Pancreatitis
- • Abdominal surgery
- • Eating disorder
- • Use of supplements containing vitamin B12 in the last year
- • Vitamin B12 injection treatment in the last year
- • Use of metformin, protein pump inhibitors or H2-receptor blockers
About University Of Helsinki
The University of Helsinki, a prestigious institution in Finland, is dedicated to advancing health sciences through innovative research and clinical trials. With a strong emphasis on interdisciplinary collaboration, the university engages in cutting-edge studies that aim to improve patient outcomes and contribute to the global knowledge base in medicine. Its commitment to ethical standards and rigorous methodology ensures the integrity and reliability of its clinical research initiatives, making it a key player in the development of novel therapeutic strategies and healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Anne-Maria Pajari, PhD
Principal Investigator
University of Helsinki
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported